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Significance of this study
What is already known on this subject?
 ► Epidemiological data for gastroparesis are 
sparse and limited to studies performed in the 
USA.
 ► Further studies are required to evaluate the 
impact and unmet need of gastroparesis in 
different populations outside of the USA.
What are the new findings?
 ► During 2016, the overall period prevalence of 
diagnosed gastroparesis was 13.8 (95% CI 12.6 
to 15.1) per 100 000 persons in the UK.
 ► Significant differences in prevalence were 
observed both across individual countries 
within the UK and within individual regions of 
England.
 ► Idiopathic gastroparesis was the leading 
aetiology recorded in the Clinical Practice 
Research Datalink (39.4%), although the 
proportion with diabetic gastroparesis was 
similar.
How might it impact on clinical practice in the 
foreseeable future?
 ► Our findings suggest a degree of uncertainty 
regarding best practice or therapeutic options 
for patients with gastroparesis among 
healthcare professionals in the UK.
 ► This represents an opportunity for the education 
of healthcare providers and development of 
robust clinical guidelines to ensure effective 
disease management.
 ► Insights from our study will provide important 
guidance for clinicians and policy- makers 
when considering diagnostic approaches 
for gastroparesis and support future clinical 
practice, education and decision- making with 
respect to gastroparesis in the UK.
AbSTrACT
Objective To generate real- world evidence for the 
epidemiology of gastroparesis in the UK, we evaluated 
the prevalence, incidence, patient characteristics and 
outcomes of gastroparesis in the clinical Practice 
research Datalink (cPrD) database.
Design This was a retrospective, cross- sectional 
study. Prevalence and incidence of gastroparesis were 
evaluated in the cPrD database, with linkage to hospital 
episodes statistics admitted Patient care and Office 
for national statistics mortality data. Prevalence and 
incidence were age and sex standardised to mid-2017 
UK population estimates. Descriptive analyses of 
demographics, aetiologies, pharmacological therapies 
and mortality were conducted.
results standardised prevalence of gastroparesis, as 
documented in general practice records, was 13.8 (95% 
ci 12.6 to 15.1) per 100 000 persons in 2016, and 
standardised incidence of gastroparesis rose from 1.5 
(95% ci 1.1 to 1.8) per 100 000 person- years in 2004 
to 1.9 (95% ci 1.4 to 2.3) per 100 000 person- years 
in 2016. The most common disease aetiologies were 
idiopathic (39.4%) and diabetic gastroparesis (37.5%), 
with a similar distribution of type 1 and type 2 diabetes 
among the 90% who had type of diabetes documented. 
Patients with diabetic gastroparesis had a significantly 
higher risk of mortality than those with idiopathic 
gastroparesis after diagnosis (adjusted hr 1.9, 95% ci 
1.2 to 3.0). Of those with gastroparesis, 31.6% were not 
offered any recognised pharmacological therapy after 
diagnosis.
Conclusion This is, to our knowledge, the first 
population- based study providing data on epidemiology 
and outcomes of gastroparesis in europe. Further 
research is required to fully understand the factors 
influencing outcomes and survival of patients with 
gastroparesis.
InTrODuCTIOn
Gastroparesis is a motility disorder characterised 
by the presence of chronic upper GI symptoms 
and delayed gastric emptying in the absence of 
mechanical obstruction.1 Established risk factors 
include, but are not limited to, the presence of 
diabetes, a history of abdominal or oesophageal 
surgery, increasing age, and use of alcohol and 
tobacco.2–4 Cardinal symptoms and signs for gast-
roparesis include early satiety, upper abdominal 
pain, nausea, vomiting, persistent anorexia and 
postprandial fullness; these symptoms are generally 
chronic with episodic exacerbations.5 Increasing 
symptom severity may be associated with detri-
mental effects on patients’ quality of life, as well 
as coexistent anxiety and depression,4 6 and results 
in increased morbidity and mortality.7 The impact 
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of gastroparesis on daily life is well documented both in terms 
of deteriorating patient quality of life and productivity, and 
the direct and indirect economic burdens placed on healthcare 
providers and society.8 9 The impact of gastroparesis is such 
that, in one study, patients were willing to accept a median 
13.4% risk of death to cure their symptoms using a hypothetical 
medication.10
Despite these detrimental effects, epidemiological data on this 
disease are limited, and most studies have been conducted in 
referral settings.11–14 The only true population- based epidemio-
logical study, from Olmsted County, Minnesota, USA, estimated 
the standardised prevalence of gastroparesis to be 24.2 per 100 
000 persons and the standardised incidence to be 6.3 per 100 
000 person- years.7 In this study, gastroparesis was more common 
in women than in men.7 However, owing to the relatively homo-
geneous local population, findings from Olmsted County may 
not accurately reflect the entire US population or populations 
of other countries,15 16 such as those in the UK. Furthermore, 
as there is considerable overlap between the symptoms of gast-
roparesis and functional dyspepsia,17 differences in payment 
systems and management guidelines between the USA and the 
UK may affect the diagnosis and reporting of gastroparesis.4 18 19 
In addition, the prevalence of some of the main risk factors for 
gastroparesis, such as diabetes, differ between the general popu-
lations of the USA and the UK.20 21
The findings of region- specific US studies, therefore, provide 
limited insights into the epidemiology of gastroparesis in the UK 
and, correspondingly, there remains a paucity of community- 
based data for gastroparesis both in the UK and Europe overall. 
To mitigate this deficit in knowledge, we conducted an observa-
tional epidemiological study that evaluated the prevalence and 
incidence of diagnosed gastroparesis in the UK general popula-
tion, using electronic health records (EHRs) from the Clinical 
Practice Research Datalink (CPRD) database. We also examined 
the demographics, clinical characteristics, potential aetiologies 
and therapies offered to UK patients with gastroparesis.
MeTHODS
Study design and data source
This retrospective cross- sectional study was conducted in the 
UK CPRD database. The CPRD is a source of real- world data 
providing a longitudinal, representative UK population health 
data set that encompasses over 35 million patient lives. This 
population- based, anonymised database stores fully coded 
patient EHRs from general practitioners (GPs) in a primary care 
setting and covers more than 11.3 million patients from 674 
general practices in the UK.22 With 4.4 million active patients 
meeting quality criteria, the CPRD covers approximately 7% of 
the UK population.23 Patients broadly represent the UK general 
population and, for over half of patients, the amount of available 
data is increased through linkage with data sets from secondary 
care, disease- specific cohorts and mortality records.23 For this 
study, CPRD primary care data with linkage to the Hospital 
Episodes Statistics (HES) for Admitted Patient Care data were 
used,24 along with UK Office for National Statistics (ONS) 
mortality data for vital status and death date.25
Study population
All patients registered in the CPRD for at least 1 day from 2000 
to 2016 were included. Cases of gastroparesis were identified 
using Read codes (online supplementary table S1). Data entered 
into the CPRD are measured by two sets of data quality criteria, 
namely patient acceptability and ‘up- to- standard’ dates. The 
‘up- to- standard’ date is a practice- based quality metric, which 
reflects the latest date at which practices meet CPRD’s minimum 
quality criteria for research purposes.23
Incidence
Incidence was calculated during each calendar year from 2004 
to 2016. The incident study population was all at- risk patients 
(ie, those with no previous diagnosis of gastroparesis) during 
each study year. Incident cases were therefore those patients 
in the incidence study population who had a new diagnosis of 
gastroparesis made during subsequent follow- up. At least 1 year 
of gastroparesis- free registration was required to minimise the 
possibility of misclassification of a prevalent case as incident, 
following registration with a new practice.26
Prevalence
A cross- sectional analysis was conducted for period prevalence 
through 2016 for the most up- to- date prevalence. The study 
population was all patients with at least 1 day of registration in 
2016. Prevalent cases of gastroparesis were patients in the prev-
alent study population who had a diagnosis of gastroparesis on 
or before 31 December 2016.
Study variables
Study variables included patient demographics: age at diagnosis, 
sex, body mass index (BMI), and lifestyle factors for tobacco 
and alcohol intake; length of enrolment in the CPRD; follow- up 
for patient demographics (online supplementary table S2); 
comorbid conditions contributing to the Charlson Comorbidity 
Index; potential aetiologies; pharmacological therapies offered 
to patients with gastroparesis, including metoclopramide, 
domperidone, erythromycin, cisapride and prucalopride (online 
supplementary table S3).
Known causes of gastroparesis, including diabetes mellitus and 
other rarer causes such as Parkinson’s disease, multiple sclerosis 
and scleroderma, were identified as potential underlying aetiolo-
gies, using all historical data prior to a diagnosis of gastroparesis 
being made.27 Postsurgical gastroparesis was considered as the 
cause for patients who had undergone surgeries that may injure 
the vagus nerve, from up to 1 year prior to a diagnosis of gast-
roparesis, but who had no history of the aforementioned condi-
tions. Similarly, drug- induced gastroparesis was considered the 
underlying aetiology for patients who had been using medication 
with the potential to delay gastric emptying, including selected 
opioid analgesics, calcium- channel blockers and anticholinergic 
agents (online supplementary table S4) within 90 days prior to 
a diagnosis of gastroparesis. The remaining patients with no 
record of any potential known cause of gastroparesis were clas-
sified as having an idiopathic aetiology.
Statistical analysis
Crude prevalence was calculated using the number of prevalent 
cases and the number of CPRD enrolees with at least 1 day of 
enrolment in 2016.
 Prevalence (crude) =
All prevalent cases between 1 Jan and 31 Dec 2016
All CPRD patients enrolled between 1 Jan and 31 Dec 2016 
For crude incidence, the entire CPRD population who did not 
have gastroparesis were considered at risk. At- risk person- time 
ended at the earliest occurrence of gastroparesis diagnosis, death 
(online supplementary text S2 and online supplementary table 
S5), eligibility discontinuation or the end of the study year.
 
 Incidence (crude) =
All incident cases between 1 Jan and 31 Dec of study year
Sum of at−risk person−time between 1 Jan and 31 Dec of study year 
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Figure 1 Flow chart of identification of patients with gastroparesis. 
CPRD, Clinical Practice Research Datalink.
Table 1 Demographics and characteristics of patients with 
gastroparesis in the CPRD
Study variable
Patients with gastroparesis
(n=1135)
Sex, n (%)
  Female 723 (63.7)
  Male 412 (36.3)
Age at first gastroparesis diagnosis, years
  Mean (SD) 50.6 (20.1)
Ethnicity, n (%)
  n 608
  White 517 (85.0)
  Asian 74 (12.2)
  Other 17 (2.8)
Body weight, kg
  n 709
  Mean (SD) 74.2 (20.8)
BMI, kg/m2
  n 687
  Mean (SD) 27.2 (8.1)
  Median (Q1, Q3) 26.5 (22.3, 31.0)
BMI category, n (%)
  n 687
  Underweight (<18.5 kg/m2) 51 (7.4)
  Normal (18.5–<25 kg/m2) 226 (32.9)
  Overweight (25–<30 kg/m2) 194 (28.2)
  Class I obesity (30–<35 kg/m2) 139 (20.2)
  Class II obesity (35–<40 kg/m2) 44 (6.4)
  Class III obesity (≥40 kg/m2) 33 (4.8)
HbA1c, mmol/mol
  n 357
  Mean (SD) 66.5 (25.1)
Alcohol use, n (%)
  Never 177 (15.6)
  Former 136 (12.0)
  Current 582 (51.3)
  Unknown 240 (21.1)
Smoking status, n (%)
  Never 324 (28.5)
  Former 453 (39.9)
  Current 214 (18.9)
  Unknown 144 (12.7)
Duration of CPRD registration before index date, years
  Mean (SD) 9.1 (5.8)
Duration of follow- up post- index date, years
  Mean (SD) 4.7 (3.4)
Charlson Comorbidity Index
  Mean (SD) 1.8 (2.0)
  Median (Q1, Q3) 1.0 (0.0, 3.0)
Charlson Comorbidity Index category
  0 378 (33.3)
  1–2 439 (38.7)
  3–4 204 (18.0)
  >=5 114 (10.0)
Comorbidities, n (%)
  Cancer 109 (9.6)
  Cerebrovascular disease 75 (6.6)
  Congestive heart failure 37 (3.3)
Continued
Crude prevalence and incidence were age and sex standardised 
to the mid-2017 UK population estimate, based on national 
census data. A Poisson distribution was used to calculate 95% 
CIs for prevalence and incidence.
Subgroup analyses were conducted for each sex, age group 
and geographical region using point prevalence on 1 July 2016. 
For chronic conditions like gastroparesis, period prevalence and 
point prevalence usually yield similar findings.
HES–ONS linked data are limited to patients in England. 
To minimise misclassification caused by missing data, overall 
survival was summarised for all patients with gastroparesis in 
England using the Kaplan- Meier product- limit life table method. 
The survival of diabetic gastroparesis versus idiopathic gastropa-
resis was compared using a multivariate Cox regression model 
to control for predictors in study variables. All available pre- 
diagnosis data were used to determine the medical history of 
each patient.
Data cleaning and analysis were conducted in SAS Enterprise 
Guide V.6.1 (Cary, NC, USA).
Patient and public involvement
Patients or the public were not involved in the design, conduct, 
reporting or dissemination plans of our research.
reSulTS
In total, 1145 cases of gastroparesis were identified for prev-
alence analysis, from a total of 11 576 068 individuals regis-
tered in the CPRD on or before 31 December 2016. In all, 
1135 patients (99.1%) were eligible for demographic analysis 
and 1045 patients (91.3%) were eligible for incidence analysis 
(figure 1).
Patient population
Among the 1135 patients providing data for demographic anal-
ysis (table 1), the average duration of CPRD registration prior to 
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Study variable
Patients with gastroparesis
(n=1135)
  Chronic pulmonary disease 309 (27.2)
  Dementia 13 (1.1)
  Diabetes with complications 308 (27.1)
  Diabetes 118 (10.4)
  Hemiplegia or paraplegia 13 (1.1)
  HIV/AIDS 3 (0.3)
  Myocardial infarction 50 (4.4)
  Mild liver disease 21 (1.9)
  Moderate or severe liver disease 6 (0.5)
  Metastatic solid tumour 7 (0.6)
  Peptic ulcer disease 92 (8.1)
  Peripheral vascular disease 60 (5.3)
  Renal disease 147 (13.0)
  Rheumatic disease 69 (6.1)
AIDS, acquired immunodeficiency syndrome; BMI, body mass index; CPRD, 
Clinical Practice Research Datalink; HbA1c, glycated haemoglobin; HIV, human 
immunodeficiency virus; SD, standard deviation.
Table 1 Continued Table 2 Aetiology for gastroparesis in the CPRD
Aetiology
number (%) of patients with 
gastroparesis
(n=1135)
Idiopathic gastroparesis 447 (39.4%)
Diabetic gastroparesis 426 (37.5%)
  Type 1 diabetes 220 (19.4%)
  Type 2 diabetes 162 (14.3%)
  Type not specified 44 (3.9%)
Drug- induced gastroparesis
  At least one drug with potential for delayed 
gastric emptying
223 (19.6%)
  Opioid analgesics 152 (13.4%)
  Calcium- channel blockers 57 (5.0%)
  Anticholinergic agents 33 (2.9%)
Postsurgical gastroparesis 13 (1.1%)
Parkinson’s disease 10 (0.9%)
Multiple sclerosis 7 (0.6%)
Cerebral palsy 3 (0.3%)
Systemic lupus erythematosus 3 (0.3%)
Scleroderma 3 (0.3%)
CPRD, Clinical Practice Research Datalink.
the date of diagnosis was 9.1 years, with an average follow- up 
duration of 4.7 years. The majority of patients were female 
(63.7%) with a mean age of 50.6 years at the time of diagnosis. 
Of the 608 patients with ethnicity recorded, the majority were 
white (85.0%), 12.2% were of Indian, Pakistani, Bangladeshi, 
Chinese or other Asian ethnicity, and 2.8% were of other ethnic-
ities. With respect to lifestyle factors, 51.3% of the patients 
were current consumers of alcohol and, of the patients with a 
recorded smoking status, 67.3% of the population were current 
or former smokers. Completeness of data for BMI in the study 
population was similar to that of the overall CPRD population.28 
Of the 687 patients (60.5% of the study population) with gast-
roparesis with available BMI data, the mean BMI was 27.2 kg/
m2. Only 226 patients (32.9%) were of a normal weight and 51 
patients (7.4%) were underweight, whereas the remaining 410 
patients (59.7%) were overweight or obese. The most frequent 
aetiology was idiopathic (39.4%), with diabetic (37.5%) and 
drug- induced (19.6%) gastroparesis being the two next most 
common aetiologies. All other aetiologies were rare (<2%) in 
the study population (table 2).
Incidence
The standardised overall incidence of gastroparesis rose from 
1.5 (95% CI 1.1 to 1.8) per 100 000 person- years in 2004 to 
1.9 (95% CI 1.4 to 2.3) per 100 000 person- years in 2016. 
However, overall incidence of gastroparesis was low, and fluc-
tuated between 1.3 and 2.1 per 100 000 person- years during 
2004–2016 (figure 2). Similar to observations seen for preva-
lence, incidence of gastroparesis was higher in women than in 
men at each time point during 2004–2016. There were too few 
incident patients each year to allow meaningful analysis for each 
age category or region, according to year.
Prevalence
During 2016, the overall period prevalence of gastroparesis 
was 13.8 (95% CI 12.6 to 15.1) per 100 000 persons in the 
UK. Subgroup analyses for point prevalence on 1 July 2016 by 
region, sex and age revealed several interesting findings. Signifi-
cant regional differences were observed within the UK (figure 3). 
Scotland had the highest prevalence at 31.7 (95% CI 27.1 to 
36.3) per 100 000 persons. Several other regions also had a 
higher prevalence than the national average, including Northern 
Ireland (23.6 (95% CI 16.0 to 31.2)), North East England (20.9 
(95% CI 2.6 to 39.2)), East of England (20.0 (95% CI 11.8 to 
28.2)) and North West England (17.9 (95% CI 11.9 to 23.9)). 
Other regions demonstrated a lower- than- average prevalence, 
such as Wales (9.2 (95% CI 6.7 to 11.7)) and London (with the 
lowest recorded prevalence at 8.4 (95% CI 5.2 to 11.6)). Preva-
lence in women was almost twofold than in men (20.4 (95% CI 
17.0 to 23.8) vs 10.3 (95% CI 7.8 to 12.8)) (table 3). Subgroup 
analysis also demonstrated that diagnosis of gastroparesis in chil-
dren (younger than 18 years) was infrequent; paediatric preva-
lence was only 3.6 (95% CI 1.2 to 6.0) in the CPRD.
Outcomes
Following diagnosis, 776 patients (68.4%) were prescribed at 
least one prokinetic (table 4), with the remaining 359 patients 
(31.6%) being offered no recognised pharmacological therapy. 
The most commonly prescribed medications were domperidone 
in 46.6% and metoclopramide in 22.9% of patients. Erythro-
mycin had been prescribed for 6.2% of patients, while prucalo-
pride and cisapride were prescribed for <1% patients.
Diabetic versus idiopathic gastroparesis
Patients with type 2 diabetic gastroparesis differed from those 
with type 1 diabetic and idiopathic gastroparesis in several notable 
factors (table 5). They were older at the time of diagnosis (62.6 
years vs 46.3 years in type 1 diabetic and 44.5 years in idiopathic 
gastroparesis). In addition, a higher proportion of patients with 
diabetic gastroparesis were overweight or obese than those with 
idiopathic gastroparesis (78.1% of type 2 diabetic and 56.4% 
of type 1 diabetic vs 52.3% of idiopathic gastroparesis). After 
multivariate Cox regression, patients with idiopathic gastropa-
resis had a significantly higher survival probability than patients 
with diabetic gastroparesis, after adjusting for significant predic-
tors in this study population, including age, sex, and presence 
of cancer, cerebrovascular disease, chronic pulmonary disease, 
peripheral vascular disease and renal disease. The adjusted HR 
 o
n
 June 26, 2020 at BVA. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2020-321277 on 3 June 2020. Downloaded from 
5Ye Y, et al. Gut 2020;0:1–10. doi:10.1136/gutjnl-2020-321277
Stomach
Figure 2 Standardised incidence of gastroparesis in the Clinical Practice Research Datalink, 2004–2016.
Figure 3 Regional prevalence of gastroparesis in the Clinical Practice Research Datalink (CPRD). (A) Prevalence of gastroparesis by country in the 
CPRD. (B) Prevalence of gastroparesis by region in England. Prevalence is shown as point prevalence on 1 July 2016.
for death was 1.9 (95% CI 1.2 to 3.0) in diabetic versus idio-
pathic gastroparesis (figure 4). Patients with both type 1 diabetic 
gastroparesis (adjusted HR 2.6, 95% CI 1.6 to 4.2) and type 
2 diabetic gastroparesis (adjusted HR 2.0, 95% CI 1.2 to 3.4) 
had a significantly higher risk of mortality than patients with 
idiopathic gastroparesis. However, type of diabetes and general 
predictors of mortality listed previously were not significantly 
associated with mortality in patients with diabetic gastroparesis 
in the CPRD.
DISCuSSIOn
To our knowledge, this is the first population- based epidemio-
logical study providing real- world evidence on the prevalence 
and incidence of gastroparesis in a European country. Our data 
suggest that the age- standardised and sex- standardised preva-
lence of documented gastroparesis was 13.8 per 100 000 persons 
in the UK in 2016, and that the standardised incidence ranged 
from 1.5 to 1.9 per 100 000 person- years between 2004 and 
2016. Although this estimated prevalence may not seem high, 
gastroparesis still represents a substantial unmet need in the UK 
because there are currently no approved treatments, and in our 
study more than 30% of patients were not offered any pharma-
cological therapy following diagnosis.
The previous study in Olmsted County, Minnesota estimated 
the prevalence of gastroparesis at 24.2 per 100 000 persons and 
the incidence to be 6.3 per 100 000 person- years.7 These results 
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Table 3 Subgroup analysis for prevalence of gastroparesis by region, 
sex and age*
Subgroups
Patients with 
gastroparesis
Population in 
the CPrD
Standardised 
prevalence (95% CI)
Region
UK (overall) 479 2 926 268 15.4 (13.3 to 17.5)
England
  East of England 23 118 333 20.0 (11.8 to 28.2)
  East Midlands† NA NA NA
  London 27 304 711 8.4 (5.2 to 11.6)
  North East 5 24 323 20.9 (2.6 to 39.2)
  North West 34 192 228 17.9 (11.9 to 23.9)
  South East 71 613 002 11.4 (8.8 to 14.1)
  South West 22 175 789 13.0 (7.5 to 18.5)
  West Midlands 24 188 643 12.4 (7.4 to 17.4)
  Yorkshire and the Humber 3 21 963 12.5 (0.0 to 26.6)
Scotland 180 570 821 31.7 (27.1 to 36.3)
Northern Ireland 37 148 300 23.6 (16.0 to 31.2)
Wales 53 568 155 9.2 (6.7 to 11.7)
Sex
  Male 170 1 447 569 10.3 (7.8 to 12.8)
  Female 309 1 478 699 20.4 (17.0 to 23.8)
Age group in years
  0–17 14 595 958 3.6 (1.2 to 6.0)
  18–29 41 414 863 8.2 (5.1 to 11.3)
  30–39 58 392 033 11.8 (7.6 to 15.9)
  40–49 78 411 954 18.4 (11.2 to 25.5)
  50–59 93 407 911 22.4 (14.9 to 29.9)
  60–69 85 322 436 28.3 (18.4 to 38.3)
  70–79 61 229 605 23.7 (16.5 to 31.0)
  80+ 49 151 508 30.7 (18.8 to 42.6)
*Subgroup analysis used point prevalence on 1 July 2016.
†General practices in East Midlands did not contribute to the CPRD in 2016.
CPRD, Clinical Practice Research Datalink; NA, not applicable.
Table 4 Pharmacological therapies for gastroparesis in the CPRD
Treatment for gastroparesis
number (%) of patients 
with gastroparesis
(n=1135)
Received at least one treatment for gastroparesis 776 (68.4%)
  Domperidone 529 (46.6%)
  Metoclopramide 260 (22.9%)
  Erythromycin 70 (6.2%)
  Prucalopride 7 (0.6%)
  Cisapride 5 (0.4%)
CPRD, Clinical Practice Research Datalink.
Table 5 Demographic characteristics of patients with type 1 diabetic, 
type 2 diabetic and idiopathic gastroparesis in the CPRD
Study variable
Type 1 diabetes Type 2 diabetes Idiopathic
(n=220) (n=162) (n=447)
Sex, n (%)
  Female 133 (60.5) 111 (68.5) 273 (61.1)
  Male 87 (39.5) 51 (31.5) 174 (38.9)
Age at first gastroparesis diagnosis, years
Mean (SD) 46.3 (16.1) 62.6 (12.2) 44.5 (21.7)
Ethnicity, n (%)
  n 119 97 230
  White 108 (90.8) 73 (75.3) 191 (83.0)
  Asian 11 (9.2) 17 (17.5) 35 (15.2)
  Other 0 (0.0) 7 (7.2) 4 (1.7)
Body weight, kg
  n 181 150 214
  Mean (SD), kg 75.4 (20.4) 82.2 (21.3) 69.2 (20.4)
BMI, kg/m2
  n 179 150 199
  Mean (SD) 26.4 (6.5) 30.2 (7.0) 26.3 (10.6)
  Median (Q1, Q3) 25.4 (22.2, 30.4) 30.4 (25.5, 33.5) 25.3 (21.1, 29.3)
BMI category, n (%)
  n 179 150 199
  Underweight (<18.5 kg/m2) 14 (7.8) 4 (2.7) 20 (10.1)
  Normal (18.5–<25 kg/m2) 64 (35.8) 29 (19.3) 75 (37.7)
  Overweight (25–<30 kg/m2) 50 (27.9) 37 (24.7) 62 (31.2)
  Class I obesity (30–<35 kg/m2) 36 (20.1) 51 (34.0) 27 (13.6)
  Class II obesity (35–<40 kg/m2) 7 (3.9) 16 (10.7) 10 (5.0)
  Class III obesity (≥40 kg/m2) 8 (4.5) 13 (8.7) 5 (2.5)
HbA1c, mmol/mol
  n 185 145 11
  Mean (SD) 72.9 (25.8) 63.3 (21.8) 36.7 (4.7)
Alcohol use, n (%)
  Never 30 (13.6) 36 (22.2) 61 (13.6)
  Former 46 (20.9) 35 (21.6) 23 (5.1)
  Current 115 (52.3) 65 (40.1) 236 (52.8)
  Unknown 29 (13.2) 26 (16.0) 127 (28.4)
Smoking status, n (%)
  Never 44 (20.0) 31 (19.1) 165 (36.9)
  Former 92 (41.8) 91 (56.2) 153 (34.2)
  Current 57 (25.9) 24 (14.8) 66 (14.8)
  Unknown 27 (12.3) 16 (9.9) 63 (14.1)
Duration of registration before index date, years
  Mean (SD) 8.9 (6.0) 10.7 (6.0) 8.4 (5.7)
Duration of follow- up post- index date, years
  Mean (SD) 4.3 (3.2) 3.9 (2.7) 5.2 (3.5)
Charlson Comorbidity Index
  Mean (SD) 3.4 (1.9) 3.4 (2.0) 0.7 (1.2)
  Median (Q1, Q3) 3.0 (2.0, 4.0) 3.0 (2.0, 5.0) 0.0 (0.0, 1.0)
Charlson Comorbidity Index category, 
n (%)
  0 0 (0.0) 0 (0.0) 266 (59.5)
  1–2 93 (42.3) 66 (40.7) 149 (33.3)
  3–4 78 (35.5) 54 (33.3) 27 (6.0)
  >=5 49 (22.3) 42 (25.9) 5 (1.1)
Comorbidities, n(%)
  Cancer 12 (5.5) 25 (15.4) 40 (8.9)
  Cerebrovascular disease 28 (12.7) 16 (9.9) 11 (2.5)
  Congestive heart failure 12 (5.5) 11 (6.8) 6 (1.3)
  Chronic pulmonary disease 60 (27.3) 53 (32.7) 95 (21.3)
  Dementia 2 (0.9) 4 (2.5) 0 (0.0)
  Diabetes with complications 206 (93.6) 102 (63.0) 0 (0.0)
  Diabetes 14 (6.4) 60 (37.0) 0 (0.0)
  Hemiplegia or paraplegia 1 (0.5) 2 (1.2) 2 (0.4)
  HIV/AIDS 0 (0.0) 1 (0.6) 0 (0.0)
  Myocardial infarction 16 (7.3) 8 (4.9) 14 (3.1)
Continued
lack generalisability to the UK general population because they 
were collected in an ethnically homogeneous local population; 
the study population was greater than 90% White,29 as opposed 
to 85% White, 12.2% of Indian, Pakistani, Bangladeshi, Chinese 
or other Asian ethnicity, and 2.8% another ethnicity in our repre-
sentative nationwide sample from the CPRD.30 Another US study 
that examined a national EHR database reported that 0.16% of 
charts (not patients) had a diagnosis of gastroparesis recorded.31 
However, the result was not standardised by demographic vari-
ables, such as age and sex, in order to estimate a population- 
based disease prevalence. The applicability of these findings to 
other countries and populations is therefore questionable.
We found that the majority of patients with gastroparesis 
in the CPRD were overweight or obese. Contrary to previous 
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Study variable
Type 1 diabetes Type 2 diabetes Idiopathic
(n=220) (n=162) (n=447)
  Mild liver disease 6 (2.7) 6 (3.7) 5 (1.1)
  Moderate or severe liver disease 3 (1.4) 1 (0.6) 0 (0.0)
  Metastatic solid tumour 0 (0.0) 1 (0.6) 3 (0.7)
  Peptic ulcer disease 14 (6.4) 13 (8.0) 30 (6.7)
  Peripheral vascular disease 28 (12.7) 16 (9.9) 6 (1.3)
  Renal disease 58 (26.4) 43 (26.5) 18 (4.0)
  Rheumatic disease 15 (6.8) 12 (7.4) 14 (3.1)
AIDS, acquired immunodeficiency syndrome; BMI, body mass index; CPRD, Clinical Practice Research Datalink; HbA1c, glycated 
haemoglobin; HIV, human immunodeficiency virus; SD, standard deviation.
Table 5 Continued
Figure 4 Survival of patients with diabetic and idiopathic gastroparesis in the Clinical Practice Research Datalink.
beliefs,32 this evidence from a real- world setting suggests that 
the chronic nausea and vomiting associated with gastroparesis 
may not always lead to weight loss. The coexistence of obesity 
should, therefore, not preclude consideration of gastroparesis as 
a potential cause of upper GI symptoms, especially in patients 
with type 2 diabetes. To put these results in context, mean BMI 
among patients with gastroparesis in the Olmsted County study 
was 24.9±6.8 versus 27.2±8.1 in the CPRD.7 A higher propor-
tion of patients with type 2 diabetic gastroparesis in the CPRD 
were overweight or obese than those with type 1 diabetic gast-
roparesis or idiopathic gastroparesis. Given the association of 
obesity with an increased risk of developing insulin resistance 
and type 2 diabetes mellitus,33 this is perhaps not surprising. 
However, our observation that approximately 50% of patients 
with idiopathic gastroparesis were also overweight or obese 
supports data reported by the NIH consortium in the USA.17 34 
On further investigation, Parkman et al concluded that patients 
with idiopathic gastroparesis consume and expend less calories 
than healthy controls, and postulated that weight gain could be 
possible in the presence of less severe symptoms.35 Without infor-
mation on the severity of symptoms, we are unable to address 
this hypothesis in CPRD and further research is required.
Other than underlying patient factors, the structure of the 
UK healthcare system may partially contribute to the differences 
in results between our study and previous published literature. 
Given that the symptom pattern of gastroparesis and functional 
dyspepsia overlap closely, it can be very difficult to distinguish 
between these two conditions on clinical grounds without gastric 
emptying tests. Over 80% of patients with gastroparesis met 
criteria for functional dyspepsia in one study.17 Gastroenter-
ologists may not refer patients for a gastric emptying study in 
the absence of more concerning symptoms that raise suspicion 
of a diagnosis of gastroparesis, such as vomiting or weight loss. 
Also of relevance is the fact that symptom management will be 
the same regardless of the gastric emptying study results, except 
in severe cases in which invasive treatments, such as gastro- 
electrical stimulation or botulinum toxin injection,36–38 may be 
required. In addition, the most widely used prokinetic agents 
in the UK, domperidone and metoclopramide, are restricted to 
short- term use only, owing to safety concerns regarding cardiac 
arrhythmias and extrapyramidal symptoms.39–41
There are also the financial pressures experienced by the 
National Health Service, which are reflected in healthcare 
policy, which may affect the willingness of GPs to refer patient 
groups with symptoms considered to be less severe, owing to 
the associated costs. In the case of gastroparesis, and the overlap 
of symptoms with functional dyspepsia, this is illustrated by the 
National Institute for Health and Care Excellence guideline for 
the management of dyspepsia,18 19 which since 2004 has discour-
aged early referral for endoscopy in patients with presumed 
dyspepsia without alarming symptoms. Instead, this guideline 
recommends that these patients are managed in primary care, 
with either empirical proton pump inhibitor therapy or testing 
for, and treatment of, Helicobacter pylori.18 Implementation of 
this guidance may have reduced the number of patients with 
presumed functional dyspepsia, who actually have gastroparesis, 
reaching secondary care. These changes to healthcare policy 
over the past 15 years, which coincide with the timeframe of 
this study, could also have altered the recorded incidence and 
prevalence of gastroparesis in the UK, and the true incidence and 
prevalence may actually be higher than we report.
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Our subgroup analysis showed statistically significant vari-
ability among countries and regions of the UK. Scotland had 
the highest prevalence of all areas studied at 31.7 per 100 000 
persons, almost four times the lowest recorded prevalence, 
which was seen in London. Variation in modifiable risk factors 
for gastroparesis, as well as social and environmental factors, 
between Scottish and Northern Irish populations and the rest of 
the UK has previously been noted, and Scotland and Northern 
Ireland have been found to have higher rates of cancer, cardio-
vascular disease and obesity than the rest of the UK.42–44 The 
general population of Scotland also has a higher mortality, which 
cannot be fully explained by sociodemographic or behavioural 
factors.43 45 When considering our results in this context, the 
higher prevalence of gastroparesis in Scotland and Northern 
Ireland may, in part, result from lifestyle factors, but may be 
further affected by socioeconomic influences within these popu-
lations. Another potential contributor to the regional differences 
we observed may be region- specific variation in education and 
training received regarding the investigation and management of 
upper GI symptoms, meaning that GPs in one region are more 
likely to make a diagnosis of functional dyspepsia, and others in 
another area gastroparesis. As previously reported in the litera-
ture, gastroparesis was seen to predominate in women compared 
with men in this study. Female predominance was seen in every 
region studied, with an almost 2:1 ratio in the UK as a whole, 
although this is less than the 4:1 ratio previously reported in 
Olmsted County.7
There has been no consensus on predominant aetiology, but 
idiopathic and diabetic gastroparesis are considered to be the 
most common causes.11 12 46 In our study population, approx-
imately 40% of patients were deemed to have idiopathic gast-
roparesis, and a similar proportion of patients had a diabetic 
aetiology. In the previous study in Olmsted County, 49% of 
patients were deemed to have idiopathic gastroparesis versus 
25% of patients who were recorded as having diabetic gast-
roparesis.7 This discrepancy in recorded disease aetiologies 
for patients with gastroparesis between the UK and the USA 
has been noted previously,47 and again suggests substantial 
differences in the investigation of upper GI symptoms, disease 
awareness, and labelling of the condition between the UK and 
the USA. Among the 223 patients who were judged as having 
drug- induced gastroparesis, the third most common cause in 
CPRD, 152 (amounting to 13% of the entire study population) 
were using opioid analgesic. Indications for prescriptions are 
not available in the CPRD database, so we are unable to unpick 
whether opioids were prescribed for abdominal pain, which is 
a symptom of gastroparesis, or whether their use predated the 
diagnosis. Certainly, abdominal pain as a recorded complaint 
was not common; only 14% had documented abdominal pain 
within the 3 months prior to opioid initiation.
To our knowledge, this is the first population- based epidemio-
logical study to investigate the prevalence and incidence of gast-
roparesis in Europe. The database encompassed 4.4 million active 
patients who met CPRD’s quality criteria for research, providing a 
large representative sample of the UK population with substantial 
follow- up time. Misclassification between incident and prevalent 
cases, due to lack of observable person- time, was minimised by a 
sufficient baseline period of 9.1 years and a follow- up time of 4.7 
years, on average, for censoring. Extensive statistical analyses were 
conducted to ensure our results were robust and to understand the 
context of the findings. Both period prevalence and point preva-
lence were used to estimate prevalence and generated similar results, 
confirming that both measurements are reliable. Subgroup analysis 
by sex confirmed a female predominance, which has been observed 
in previous studies, although our study population had a higher 
percentage of male patients. Subgroup analyses demonstrated as 
large as a fourfold difference in prevalence across different areas of 
the UK, suggesting that the likelihood of a diagnosis of gastropa-
resis being made may differ considerably according to geography, 
and that prevalence increased steadily with age. The condition was 
rarely diagnosed among children, and prevalence was highest in 
those who were 60–69 years of age in the UK. Finally, this study 
has described the treatment, survival and aetiology of patients 
with gastroparesis in the UK. CPRD with linkage to HES–ONS 
death registry data has been shown previously to be sufficient for 
censoring follow‐up and calculating mortality.48 We demonstrate 
that patients with diabetic gastroparesis had an almost twofold 
mortality to those with idiopathic gastroparesis, after adjusting for 
significant predictors.
This study has several limitations that require consideration. 
As the CPRD is a primary care EHR database, specialist docu-
ments, such as requests for tests in, and letters from, secondary 
care, are scanned into primary care records and may, therefore, 
not be indexed by the GP practice into the database. In addition, 
handling of these documents and the associated coding may differ 
among GPs, and accuracy of assigning the correct medical or Read 
codes varies.49 50 The necessary investigations to confirm a diag-
nosis of gastroparesis, such as gastric emptying studies, are only 
available in secondary or tertiary care. This means that a failure to 
record the results of these tests in GP records, or discrepancies in 
management of documentation or coding, could lead to misclassi-
fication of patients in this primary care database. The present data 
are, therefore, only representative of patients with a diagnosis of 
gastroparesis recorded according to the study inclusion criteria. It 
may be difficult for patients to obtain a clinical diagnosis of gast-
roparesis and, as has already been discussed, it is possible that some 
patients with genuine gastroparesis may have been misdiagnosed 
with other conditions, such as functional dyspepsia, or were unable 
to acquire a referral for confirmatory diagnostic testing. Such 
misclassification would tend to underestimate both the prevalence 
and incidence of gastroparesis in our study, and suggests that any 
patients identified by the definition we used are unlikely to be free 
of gastroparesis. As a result, the true prevalence and incidence of 
gastroparesis are likely to be higher than our estimates. In addition, 
although standardised by age and sex, our study results are derived 
from a primary care population in the UK and may not, there-
fore, be directly compared with other populations and healthcare 
systems. Nevertheless, CPRD patients are broadly representative 
of the UK general population in terms of age, sex, ethnicity and 
BMI.23 Therefore, we believe that our findings are still likely to 
be representative of patients with gastroparesis diagnosed in the 
UK. We observed that the adjusted overall survival in patients with 
diabetic gastroparesis was significantly lower than that of patients 
with idiopathic gastroparesis. Although several known risk factors 
for death, including BMI, and tobacco and alcohol intake, were 
not significant predictors of death in the study population, we 
were unable to control for other potential contributors for death 
including severity of gastroparesis and specific diabetic compli-
cations in this database. In addition, despite the introduction of 
the Quality Outcomes Framework incentives for diabetes coding 
in 2004, type of diabetes was unavailable for 10% of patients 
with presumed diabetic gastroparesis. We recognise that another 
important limitation is that there is no information on symptom 
patterns among patients with gastroparesis. Our original study 
proposal had examination of this issue as an a priori objective. 
However, subsequent dataset exploration uncovered that many of 
the symptoms of interest could not be accurately identified due to 
the lack of a proper Read code or a validated algorithm.
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In conclusion, this study provides a critical addition to the 
sparse epidemiological data concerning gastroparesis in the liter-
ature. Despite limitations, this is the first population- based study 
to generate real- world evidence on the incidence and prevalence 
of gastroparesis in a European country. The study findings advance 
our knowledge related to patient characteristics, management and 
aetiology of gastroparesis in the UK. There is also a need for further 
research to understand fully the factors that may affect outcomes 
and survival of patients with gastroparesis.
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